ATE540676T1 - Egfr-inhibitoren zur behandlung und diagnose von metastasierendem prostatakrebs - Google Patents

Egfr-inhibitoren zur behandlung und diagnose von metastasierendem prostatakrebs

Info

Publication number
ATE540676T1
ATE540676T1 AT08749545T AT08749545T ATE540676T1 AT E540676 T1 ATE540676 T1 AT E540676T1 AT 08749545 T AT08749545 T AT 08749545T AT 08749545 T AT08749545 T AT 08749545T AT E540676 T1 ATE540676 T1 AT E540676T1
Authority
AT
Austria
Prior art keywords
egfr
inhibitors
prostate cancer
metastatic prostate
treatment
Prior art date
Application number
AT08749545T
Other languages
English (en)
Inventor
Anne Hansen Ree
Ase Bratland
Pieter Jacob Boender
Robby Ruijtenbeek
Original Assignee
Rikshospitalet Radiumhospitalet Hf
Pamgene Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rikshospitalet Radiumhospitalet Hf, Pamgene Bv filed Critical Rikshospitalet Radiumhospitalet Hf
Application granted granted Critical
Publication of ATE540676T1 publication Critical patent/ATE540676T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT08749545T 2007-04-13 2008-04-11 Egfr-inhibitoren zur behandlung und diagnose von metastasierendem prostatakrebs ATE540676T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200700547 2007-04-13
PCT/EP2008/054432 WO2008125633A2 (en) 2007-04-13 2008-04-11 Egfr inhibitors for treatment and diagnosis of metastatic prostate cancer

Publications (1)

Publication Number Publication Date
ATE540676T1 true ATE540676T1 (de) 2012-01-15

Family

ID=39144274

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08749545T ATE540676T1 (de) 2007-04-13 2008-04-11 Egfr-inhibitoren zur behandlung und diagnose von metastasierendem prostatakrebs

Country Status (4)

Country Link
US (1) US20100203043A1 (de)
EP (1) EP2157971B1 (de)
AT (1) ATE540676T1 (de)
WO (1) WO2008125633A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3101B1 (ar) 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co مشتقات بنزوثيازول كعوامل مضادة للسرطان
EP2560640A1 (de) 2010-04-19 2013-02-27 Synta Pharmaceuticals Corp. Krebstherapie mit einer kombination aus hsp90-inhibitorverbindungen und einem egfr-hemmer
MX2013010977A (es) 2011-03-31 2013-10-30 Procter & Gamble Sistema, modelos y metodos para identificar y evaluar agentes dermoactivos eficaces para tratar la caspa/dermatitis seborreica.
WO2012155063A1 (en) * 2011-05-11 2012-11-15 Synta Pharmaceuticals Corp. Treating cancer with an hsp90 inhibitory compound
CA2853806C (en) 2011-11-02 2020-07-14 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with platinum-containing agents
CA2853799A1 (en) 2011-11-02 2013-05-10 Synta Pharmaceuticals Corp. Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
US9402831B2 (en) 2011-11-14 2016-08-02 Synta Pharmaceutical Corp. Combination therapy of HSP90 inhibitors with BRAF inhibitors
WO2013102096A1 (en) 2011-12-30 2013-07-04 Quest Diagnostics Investments Incorporated Aptamers and diagnostic methods for detecting the egf receptor
EP2859486A2 (de) 2012-06-06 2015-04-15 The Procter & Gamble Company Systeme und verfahren zur identifizierung kosmetischer wirkstoffe für haar-/kopfhautpflegezusammensetzungen
JP2021521445A (ja) * 2018-04-13 2021-08-26 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 前立腺癌又は乳癌を患っている患者の転帰を予測するための及び処置のための方法
GB201809295D0 (en) 2018-06-06 2018-07-25 Institute Of Cancer Res Royal Cancer Hospital Lox inhibitors
GB201818750D0 (en) 2018-11-16 2019-01-02 Institute Of Cancer Res Royal Cancer Hospital Lox inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0008368D0 (en) * 2000-04-06 2000-05-24 Astrazeneca Ab Combination product
SK14632003A3 (sk) * 2001-05-08 2004-03-02 Merck Patent Gmbh Kombinovaná terapia pri použití anti-EGFR protilátok a antihormonálnych činidiel
EP1590487A2 (de) * 2003-02-06 2005-11-02 Genomic Health, Inc. Genexpressionsmarker für die antwort auf egfr-inhibitormedikamente
WO2006052249A1 (en) * 2004-11-08 2006-05-18 The Regents Of The University Of California Methods involving the pi3k/akt in gliomas and prostate cancers

Also Published As

Publication number Publication date
US20100203043A1 (en) 2010-08-12
EP2157971A2 (de) 2010-03-03
EP2157971B1 (de) 2012-01-11
WO2008125633A2 (en) 2008-10-23
WO2008125633A3 (en) 2009-05-28

Similar Documents

Publication Publication Date Title
ATE540676T1 (de) Egfr-inhibitoren zur behandlung und diagnose von metastasierendem prostatakrebs
ATE504299T1 (de) Verfahren zur behandlung von gefitinib- resistentem krebs
MX2020008976A (es) Biomarcadores y su uso en el tratamiento de condiciones relacionadas con pd-1 y pd-l1.
ATE554267T1 (de) Verfahren und systeme zur beurteilung und behandlung von zuvor frakturierten unterirdischen formationen
WO2007141280A3 (en) Proteins
TW200626900A (en) Wnt proteins and detection and treatment of cancer
TR200906131T1 (tr) Aktivin -actrIIa antagonistleri ve göğüs kanserinin tedavi e
EA201200473A1 (ru) Замещенные (гетероарилметил)тиогидантоины
EA201200597A1 (ru) Моноклональные антитела к прогастрину и их применение
NZ703411A (en) Use of markers in the diagnosis and treatment of prostate cancer
DE602005012481D1 (de) 2,7-substituierte 5-amino-4-hydroxy-8-(1h-indol-5-yl)-octanamid derivate als renin inhibitoren zur behandlung von bluthochdruck
BRPI0908635A8 (pt) composto, composição farmacêutica e método de tratamento de câncer
MX2009005725A (es) Metodos y composiciones para tratamiento y monitoreo de tratamiento de trastornos asociados con il-13.
WO2010042933A3 (en) Inhibition and treatment of prostate cancer metastasis
DE602008005715D1 (de) 2-amino-5,7-dihydro-6h-pyrroloä3,4-düpyrimidinderivate als hsp-90-inhibitoren zur behandlung von krebs
ATE428712T1 (de) 4-amino-5-oxo-8-phenyl-5h-pyrido-ä2,3-dü- pyrimidin-derivate als inhibitoren der tyrosinkinasen und der raf-kinasen zur behandlung von tumoren
WO2007033167A3 (en) Compositions and methods for detecting and treating cancer
EA201001749A1 (ru) Способ лечения недифференцированного артрита
WO2009020645A3 (en) Matriptase protein and uses thereof
GB2523211A8 (en) MCT protein inhibitor-related prognostic and therapeutic methods
WO2009091230A3 (ko) 유방암 모니터링,진단 및 스크리닝용 단백질 마커 및 이를 이용한 유방암 모니터링,진단 및 스크리닝 방법
WO2008026008A8 (en) Protein
WO2008115478A3 (en) Method of cancer detection and treatment
WO2010026473A3 (en) Pta072 protein
ATE529536T1 (de) Verfahren zur identifizierung und behandlung von komplexe karyotypen zeigenden individuen